Discover Australia as a Leading Destination for Early Phase Clinical Trials

The session will look at why so many companies are choosing Australia for early development, including:

– Faster start-up timelines (no IND required; approvals often in ~4–6 weeks)

– High-quality data accepted by global regulators such as the FDA and EMA

– Meaningful cost advantages, including access to Australia’s R&D tax incentive of up to 43.5%

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher CVille Bio Hub